Hanmi Science Co., Ltd. (KRX: 008930)

Market Cap	2.24T
Revenue (ttm)	1.27T
Net Income (ttm)	117.97B
Shares Out	67.71M
EPS (ttm)	1,739.42
PE Ratio	19.06
Forward PE	n/a
Dividend	200.00 (0.61%)
Ex-Dividend Date	Jun 27, 2024

Volume	118,347
Open	32,600
Previous Close	32,350
Day's Range	32,050 - 33,250
52-Week Range	25,750 - 56,200
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 30, 2024

About Hanmi Science

Hanmi Science Co., Ltd., through its subsidiaries, manufactures and sells pharmaceutical products in Korea and internationally. It develops drugs in the areas of diabetes and anti-cancer, as well as children's and adult’s bowel preparation and cold medicines, and cephalosporin antibiotics. The company also offers general foods, health functional foods, soy milk, and medical equipment. In addition, it offers automated drug management systems. The company sells its products through online and offline pharmacies. The company was formerly known as ...

• Industry: Medical Distribution
• Sector: Healthcare
• Founded: 1973
• Employees: 403
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 008930

Financial Performance

In 2023, Hanmi Science's revenue was 1.25 trillion, an increase of 19.30% compared to the previous year's 1.05 trillion. Earnings were 115.12 billion, an increase of 66.34%.